EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting inflammation to treat diabetic kidney disease: the road to 2030

Sandra Rayego-Mateos, Raul R Rodrigues-Diez, Beatriz Fernandez-Fernandez, Carmen Mora-Fernández, Vanessa Marchant, Javier Donate-Correa, Juan F Navarro-González, Alberto Ortiz, Marta Ruiz-Ortega

Kidney International · 2023-02 · 103 (2) · 282-296

DOI: 10.1016/j.kint.2022.10.030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2023-02. Verfasst von Sandra Rayego-Mateos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Biology in Renal Diseases Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain; Ricord2040, Instituto de Salud Carlos…. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 360-mal zitiert (Crossref) und nennt 179 Literaturangaben. Gefördert von: Universidad Autonoma de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney disease and associated morbidity and mortality. Preclinical research has demonstrated the involvement of inflammation in its pathogenesis and in the progression of kidney damage, supporting clinical trials designed to explore anti-inflammatory strategies. However, the recent success of sodium-glucose cotransporter-2 inhibitors and the nonsteroidal mineralocorticoid receptor antagonist finerenone has changed both guidelines and standard of care, rendering obsolete older studies directly targeting inflammatory mediators and the clinical development was discontinued for most anti-inflammatory drugs undergoing clinical trials for DKD in 2016. Given the contribution of inflammation to the pathogenesis of DKD, we review the impact on kidney inflammation of the current standard of care, therapies undergoing clinical trials, or repositioned drugs for DKD. Moreover, we review recent advances in the molecular regulation of inflammation in DKD and discuss potential novel therapeutic strategies with clinical relevance. Finally, we provide a road map for future research aimed at integrating the growing knowledge on inflammation and DKD into clinical practice to foster improvement of patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHumansInflammation

Stichwörter der Autor:innen

SGLT2chronic kidney diseaseclinical trialsdiabetesdiabetic kidney diseasefinerenoneinflammation

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Cellular Biology in Renal Diseases Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain; Ricord2040, Instituto de Salud Carlos II, Spain.
  • Ricord2040, Instituto de Salud Carlos II, Spain; Translational Immunology, Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Oviedo, Asturias, Spain.
  • Ricord2040, Instituto de Salud Carlos II, Spain; Division of Nephrology and Hypertension, IIS-Fundación Jiménez Díaz-Universidad Autónoma, Madrid, Spain.
  • Ricord2040, Instituto de Salud Carlos II, Spain; Research Unit, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
  • Ricord2040, Instituto de Salud Carlos II, Spain; Research Unit, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain; Nephrology Service, University Hospital Nuestra Señora de Candelaria, Sant…
  • Cellular Biology in Renal Diseases Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain; Ricord2040, Instituto de Salud Carlos II, Spain. Electronic address: mruizo@fjd.es.

Förderung

  • Universidad Autonoma de Madrid

Zitieren

APA

Rayego-Mateos, S., Rodrigues-Diez, R. R., Fernandez-Fernandez, B., Mora-Fernández, C., Marchant, V., Donate-Correa, J., Navarro-González, J. F., Ortiz, A., & Ruiz-Ortega, M. (2023). Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney International, 103(2), 282-296. https://doi.org/10.1016/j.kint.2022.10.030

Vancouver

Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney International. 2023;103(2):282-296. doi:10.1016/j.kint.2022.10.030

BibTeX
@article{RayegoMateos2023,
  author = {Rayego-Mateos, Sandra and Rodrigues-Diez, Raul R and Fernandez-Fernandez, Beatriz and Mora-Fernández, Carmen and Marchant, Vanessa and Donate-Correa, Javier and Navarro-González, Juan F and Ortiz, Alberto and Ruiz-Ortega, Marta},
  title = {Targeting inflammation to treat diabetic kidney disease: the road to 2030},
  journal = {Kidney International},
  year = {2023},
  volume = {103},
  number = {2},
  pages = {282--296},
  doi = {10.1016/j.kint.2022.10.030}
}
Kostenlos starten →